Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    778

Stocks News & Analysis

stocks

Investors punish this ASX player after acquisition

We think the floundering stock price is not reflective of underlying asset value.
stocks

Revenue growth on track for undervalued ASX healthcare stock

Near-term cost growth does not change our long-term view.
stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.3015.500.17%
CAC 408,245.8018.07-0.22%
DAX 4023,806.99273.64-1.14%
Dow JONES (US)48,185.80275.880.58%
FTSE 10010,603.485.40-0.05%
HKSE25,925.74173.340.67%
NASDAQ22,822.42187.420.83%
Nikkei 22556,948.041,052.721.88%
NZX 50 Index13,163.94109.87-0.83%
S&P 5006,824.6641.850.62%
S&P/ASX 2008,945.2020.800.23%
SSE Composite Index3,991.1424.960.63%

Market Movers